Structural changes by sulfoxidation of phenothiazine drugs
- PMID: 1355521
- DOI: 10.1007/BF00123377
Structural changes by sulfoxidation of phenothiazine drugs
Abstract
The side-chain conformations of psychoactive phenothiazine drugs in crystals are different from those of biologically inactive ring sulfoxide metabolites. This study examines the potential energies, molecular conformations and electrostatic potentials in chlorpromazine, levomepromazine (methotrimeprazine), their sulfoxide metabolites and methoxypromazine. The purpose of the study was to examine the significance of the different crystal conformations of active and inactive phenothiazine derivatives, and to determine why phenothiazine drugs lose most of their biological activity by sulfoxidation. Quantum mechanics and molecular mechanics calculations demonstrated that conformations with the side chain folded over the ring structure had lowest potential energy in vacuo, both in the drugs and in the sulfoxide metabolites. In the sulfoxides, side chain conformations corresponding to the crystal structure of chlorpromazine sulfoxide were characterized by stronger negative electrostatic potentials around the ring system than in the parent drugs. This may weaken the electrostatic interaction of sulfoxide metabolites with negatively charged domains in dopamine receptors, and cause the sulfoxides to be virtually inactive in dopamine receptor binding and related pharmacological tests.
Similar articles
-
Chlorpromazine, methotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation.Mol Pharmacol. 1982 Mar;21(2):409-14. Mol Pharmacol. 1982. PMID: 6124878
-
Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding.Biochem Pharmacol. 1986 Apr 15;35(8):1263-9. doi: 10.1016/0006-2952(86)90269-8. Biochem Pharmacol. 1986. PMID: 2870716
-
Phenothiazine drug metabolites: dopamine D2 receptor, alpha 1- and alpha 2-adrenoceptor binding.Eur J Pharmacol. 1986 Jun 24;125(3):373-81. doi: 10.1016/0014-2999(86)90793-4. Eur J Pharmacol. 1986. PMID: 2874041
-
Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents.Am J Ther. 2006 May-Jun;13(3):261-73. doi: 10.1097/01.mjt.0000212897.20458.63. Am J Ther. 2006. PMID: 16772768 Review.
-
Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects.Ther Drug Monit. 1982;4(1):33-40. doi: 10.1097/00007691-198204000-00005. Ther Drug Monit. 1982. PMID: 6122292 Review.